Mean Visual Acuity Changes Following Five Injections of Aflibercept
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Diabetic Macular Edema is a serious ocular consequence of poorly controlled diabetes. Even
though significant research has been done to clarify the pathogenesis of DME, a clear causal
pathway of the complication is of yet undetermined. However, there is some consensus among
researchers that a cascade of inflammatory markers plays an important role in the disease
process. The study hopes to better delineate the role these inflammatory markers play by
investigating whether basal levels predict response or lack thereof to Aflibercept.